Search hospitals > Nevada > Reno

Saint Mary's Regional Medical Center

Claim this profile
Reno, Nevada 89503
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Tumors
Conducts research for Adenocarcinoma
170 reported clinical trials
3 medical researchers
Photo of Saint Mary's Regional Medical Center in RenoPhoto of Saint Mary's Regional Medical Center in RenoPhoto of Saint Mary's Regional Medical Center in Reno

Summary

Saint Mary's Regional Medical Center is a medical facility located in Reno, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Tumors, Adenocarcinoma and other specialties. Saint Mary's Regional Medical Center is involved with conducting 170 clinical trials across 374 conditions. There are 3 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, and Samuel Chacon, MD.

Area of expertise

1Cancer
Global Leader
Saint Mary's Regional Medical Center has run 72 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Saint Mary's Regional Medical Center has run 33 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Saint Mary's Regional Medical Center

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Bladder Cancer
Bladder Carcinoma
Gastric Cancer
Renal Cell Carcinoma
Esophageal Cancer
Anal Cancer
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Support Program

for Breast Cancer

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Mary's Regional Medical Center?
Saint Mary's Regional Medical Center is a medical facility located in Reno, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Tumors, Adenocarcinoma and other specialties. Saint Mary's Regional Medical Center is involved with conducting 170 clinical trials across 374 conditions. There are 3 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, and Samuel Chacon, MD.